Breaking News, Collaborations & Alliances

Xyphos Biosciences and GO Enter Strategic Research Collaboration

Aim to develop novel Immuno-Oncology therapeutics.

Author Image

By: Charlie Sternberg

Associate Editor

Xyphos Biosciences Inc., a wholly owned subsidiary of Astellas, and GO have entered into a strategic research collaboration and license agreement to develop novel Immuno-Oncology therapeutics.   GO is applying new advances in glycoproteomics to develop antibody-based cancer therapeutics that specifically target cancer cells. Xyphos holds a novel and proprietary ACCELTM technology platform that uses its convertibleCAR (convertible Chimeric Antigen Receptor) on immune cells. Terms of the Agr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters